From the Guidelines
Veoza is not mentioned in the provided evidence, and therefore, its definition or description cannot be determined based on the given studies. The studies provided focus on guidelines for the management of arterial hypertension, prevention, detection, evaluation, and treatment of high blood pressure, and the management of heart failure.
Hypertension Management
The 2007 guidelines for the management of arterial hypertension suggest that the choice of antihypertensive drugs should be based on the presence of subclinical organ damage, clinical cardiovascular disease, renal disease, or diabetes, as well as the patient's previous experience with a given class of compounds and potential interactions with other drugs 1.
Lifestyle Modifications
Lifestyle modifications, such as weight reduction, adoption of the DASH eating plan, dietary sodium reduction, physical activity, and moderation of alcohol consumption, are also recommended for the prevention and management of hypertension 1.
Heart Failure Management
In the management of heart failure, ACE inhibitors, beta-blockers, and diuretics are recommended, with aldosterone antagonists providing additional benefit in patients with severe left ventricular dysfunction 1.
However, without further information or context about Veozah, it is not possible to provide a definitive answer or recommendation regarding its use or efficacy.
From the Research
Definition of Vezohah
- Vezohah, also known as Fezolinetant, is a non-hormonal treatment for vasomotor symptoms of menopause 2, 3.
- It is a neurokinin 3 receptor antagonist that targets the disrupted thermoregulation underlying vasomotor symptoms 3.
Usage and Efficacy
- Vezohah is approved by the U.S. Food and Drug Administration for the treatment of vasomotor symptoms of menopause 2.
- Clinical trials, including SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4, have established Fezolinetant's efficacy and safety profile 3, 4.
- The recommended dosage is one 45 mg tablet per day, which demonstrates proportional pharmacokinetics and generally mild side effects 3, 4.
Safety Profile
- Treatment-emergent adverse events occurred in 37% of women in the fezolinetant 30 mg group, 43% in the fezolinetant 45 mg group, and 45% in the placebo group 4.
- The incidence of liver enzyme elevations was low and these events were generally asymptomatic, transient, and resolved while on treatment or after treatment discontinuation 4.